Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012
Jabbour, S., Cho, B.C., Bria, E., Kato, T., Bhosle, J., Gainor, J.F., Reguart, N., Wang, L., Morgensztern, D., Gurary, E.B., Ashraf, T.B., Lara-Guerra, H., Reck, M.Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.151
Date:
September, 2020
File:
PDF, 83 KB
2020